PURPOSE: We aimed to find predictive tumour characteristics as detected by interim positron-emission tomography/magnetic resonance imaging (PET/MRI) in cervical cancer patients. We also investigated the type of interim response. Furthermore, we compared the investigated parameters with disease-free (DFS) and overall survival (OS) outcomes. METHODS: We evaluated 108 patients treated between August 2015 and January 2023 with external-beam radiotherapy (EBRT) and image-guided adaptive brachytherapy (IGABT) who had undergone pretreatment staging, subsequent mid-treatment evaluation after completed EBRT and definitive restaging 3 months after completing the whole treatment using PET/MRI. Patients were then divided into two groups based on the RECIST and PERCIST criteria: responders (achieving complete metabolic response, CMR) and non-responders (non-CMR). These two groups were compared using selected parameters obtained at pre-PET/MRI and mid-PET/MRI. The early response to treatment as evaluated by mid-PET/MRI was categorized into three types: interim complete metabolic response, interim nodal response and interim nodal persistence. RESULTS: Mid-TLG‑S (the sum of total lesion glycolysis for the primary tumour plus pelvic and para-aortic lymph nodes) parameter showed the best discriminatory ability for predicting non-CMR. The second factor with significant discriminatory ability was mid-MTV‑S (the sum of the metabolic tumour volume of the primary tumour plus pelvic and para-aortic lymph nodes). The strongest factor, mid-TLG‑S, showed a sensitivity of 40% and a specificity of 90% at a threshold value of 70. We found a statistically significant association of DFS and OS with the following parameters: number of chemotherapy cycles, early response type and CMR vs. non-CMR. CONCLUSION: We were able to identify thresholds for selected parameters that can be used to identify patients who are more likely to have worse DFS and OS. The type of early response during concurrent chemoradiotherapy (CCRT) was also significantly associated with DFS and OS. These aspects represent an important contribution to the possible stratification of patients for subsequent individualised adjuvant treatment.

Biomedical Center Faculty of Medicine in Pilsen Charles University alej Svobody 76 323 00 Pilsen Czech Republic

Department of Gynecology and Obstetrics University Hospital in Pilsen alej Svobody 80 304 60 Pilsen Czech Republic

Department of Imaging Methods University Hospital in Pilsen alej Svobody 80 304 60 Pilsen Czech Republic

Department of Oncology and Radiotherapy University Hospital in Pilsen alej Svobody 80 304 60 Pilsen Czech Republic

Faculty of Medicine Charles University Pilsen Czech Republic

See more in PubMed

Ferlay J, Ervik M, Lam F et al (2024) Global cancer observatory: cancer today (version 1.1). Lyon, France: international agency for research on cancer. https://gco.iarc.fr/tomorrow. Accessed 26 May 2024

Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration (2008) Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 26(35):5802–5812 PubMed PMC

Kitajima K, Suenaga Y, Ueno Y et al (2014) Fusion of PET and MRI for staging of uterine cervical cancer: comparison with contrast-enhanced (18)F-FDG PET/CT and pelvic MRI. Clin Imaging 38(4):464–469 PubMed

Sarabhai T, Tschischka A, Stebner V et al (2018) Simultaneous multiparametric PET/MRI for the assessment of therapeutic response to chemotherapy or concurrent chemoradiotherapy of cervical cancer patients: preliminary results. Clin Imaging 49:163–168 PubMed

Grueneisen J, Schaarschmidt BM, Heubner M et al (2015) Integrated PET/MRI for whole-body staging of patients with primary cervical cancer: preliminary results. Eur J Nucl Med Mol Imaging 42(12):1814–1824 PubMed

Vojtíšek R, Baxa J, Kovářová P et al (2021) Prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy. Strahlenther Onkol 197:494–504 PubMed

Vojtíšek R, Baxa J, Hošek P et al (2021) Reply to: prediction of treatment response in patients with locally advanced cervical cancer using midtreatment PET/MRI during concurrent chemoradiotherapy. In regard to Vojtíšek et al. Strahlenther Onkol 197(10):937–938 PubMed

Bhatla N, Berek JS, Cuello Fredes M et al (2019) Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 145(1):129–135 PubMed

Haie-Meder C, Pötter R, Van Limbergen E et al (2005) Gynaecological (GYN) GEC-ESTRO working group. Recommendations from gynaecological (GYN) GEC-ESTRO working group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 74(3):235–245 PubMed

Pötter R, Haie-Meder C, Van Limbergen E, GEC ESTRO Working Group et al (2006) Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 78(1):67–77 PubMed

Viswanathan AN, Thomadsen B (2012) American Brachytherapy society cervical cancer recommendations committee; American Brachytherapy society. American Brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy 11(1):33–46 PubMed

Viswanathan AN, Beriwal S, De Los SJF et al (2012) American Brachytherapy society. American Brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy 11(1):47–52 PubMed PMC

Vojtíšek R, Sukovská E, Baxa J et al (2019) Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer : institutional experiences. Strahlenther Onkol 195(11):972–981 PubMed

Vojtíšek R, Hošek P, Sukovská E et al (2022) Treatment outcomes of MRI-guided adaptive brachytherapy in patients with locally advanced cervical cancer: institutional experiences. Strahlenther Onkol 198(9):783–791 PubMed

International Commission on Radiation Units and Measurements Prescribing, recording, and reporting brachytherapy for cancer of the cervix (ICRU report 89, 2013). Bethesda

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247 PubMed

J H O, Lodge MA, Wahl RL (2016) Practical PERCIST: a simplified guide to PET response criteria in solid tumours 1.0. Radiology 280(2):576–584 PubMed PMC

Mileshkin LR, Moore KN, Barnes EH et al (2023) Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. Lancet Oncol 24(5):468–482 PubMed PMC

Hong JH, Tsai CS, Lai CH et al (2004) Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 60(1):249–257 PubMed

Rose PG, Java J, Whitney CW et al (2015) Nomograms predicting progression-free survival, overall survival, and pelvic recurrence in locally advanced cervical cancer developed from an analysis of identifiable prognostic factors in patients from NRG oncology/gynecologic oncology group randomized trials of chemoradiotherapy. J Clin Oncol 33(19):2136–2142 PubMed PMC

Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW (2007) Association of posttherapy positron emission tomography with tumour response and survival in cervical carcinoma. JAMA 298(19):2289–2295 PubMed

Liu FY, Su TP, Wang CC et al (2018) Roles of posttherapy 18F‑FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy. Eur J Nucl Med Mol Imaging 45(7):1197–1204 PubMed

Schernberg A, Bockel S, Annede P et al (2018) Tumour shrinkage during chemoradiation in locally advanced cervical cancer patients: prognostic significance, and impact for image-guided adaptive brachytherapy. Int J Radiat Oncol Biol Phys 102(2):362–372 PubMed

Herrera FG, Breuneval T, Prior JO et al (2016) (18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy. Radiat Oncol 11:43 PubMed PMC

Liu FY, Lai CH, Yang LY et al (2016) Utility of (18)F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy: a parallel study of a prospective randomized trial. Eur J Nucl Med Mol Imaging 43(10):1812–1823 PubMed

Oh D, Lee JE, Huh SJ et al (2013) Prognostic significance of tumour response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 87(3):549–554 PubMed

Xu C, Sun H, Du S, Xin J (2019) Early treatment response of patients undergoing concurrent chemoradiotherapy for cervical cancer: an evaluation of integrated multi-parameter PET-IVIM MR. Eur J Radiol 117:1–8 PubMed

Gao S, Du S, Lu Z et al (2020) Multiparametric PET/MR (PET and MR-IVIM) for the evaluation of early treatment response and prediction of tumour recurrence in patients with locally advanced cervical cancer. Eur Radiol 30(2):1191–1201 PubMed

Strandberg S, Jonsson J, Zarei M et al (2024) Baseline and early response 2‑[18F]FDG-PET/MRI for prediction of radiotherapy outcome in uterine cervical squamous cell carcinoma: a prospective single-center observational cohort study. EJNMMI Rep 8(1):5 PubMed PMC

Aerts HJ, Velazquez ER, Leijenaar RT et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5:4006 PubMed PMC

Lucia F, Visvikis D, Desseroit MC et al (2018) Prediction of outcome using pretreatment 18F‑FDG PET/CT and MRI radiomics in locally advanced cervical cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging 45(5):768–786 PubMed

Lucia F, Visvikis D, Vallières M et al (2019) External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging 46(4):864–877 PubMed

Chartrand G, Cheng PM, Vorontsov E et al (2017) Deep learning: a primer for radiologists. Radiographics 37(7):2113–2131 PubMed

McCormack M, Gallardo Rincón D, Eminowicz G et al (2023) A randomized phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: the GCIG INTERLACE trial. Ann Oncol 34:S1276. 10.1016/j.annonc.2023.10.028

Fields EC, Hazell S, Morcos M et al (2020) Image-guided gynecologic brachytherapy for cervical cancer. Semin Radiat Oncol 30(1):16–28 PubMed

https://clinicaltrials.gov/ct2/show/NCT03612791